Adapting Neurological Care Amid COVID-19
As the ongoing battle against the spread of COVID-19 continues, the medical community is learning more about the disease and at-risk populations by the day. Many symptoms and comorbidities associated with neurologic disorders place patients, especially those in the neuromuscular disease community, within those high-risk categories established by the Centers for Disease Control and Prevention […]
Dr. Barry Byrne Featured in Denison Magazine
Barry J. Byrne, M.D., Ph.D., director of the University of Florida Powell Gene Therapy Center, a professor in Pediatrics and Molecular Genetics & Microbiology, and the associate chair in Pediatrics at the University of Florida, is studying a variety of rare diseases with specific attention to developing therapies for inherited muscle disease. His development of the Powell Gene […]
MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia
The Muscular Dystrophy Association (MDA) and UF Innovate | The Hub resident client AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich’s Ataxia (FA), announced the award of MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance AavantiBio’s phase 2 clinical trial of a gene-replacement therapy for the disease. MVP is MDA’s drug development […]